SAFETY OF SGLT2 INHIBITORS IN ACTIVE CANCER PATIENTS: RATIONALE AND STUDY DESIGN OF TOSCA TRIAL

被引：0
|
作者：
Canale, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Fabiani, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Delle Donne, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Colombi, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Lupo, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Barletta, V [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Capati, E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Orso, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Arena, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Frediani, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Pasanisi, E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
De Caterina, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Zucchelli, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Emdin, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Casolo, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Camerini, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
机构：
[1] Versilia Hosp Azienda Usl Toscana Nord Ovest, Cardiol, Lido Di Camaiore, Italy
[2] Fdn Toscana Gabriele Monasterio, Cardiol Div, Pisa, Italy
[3] Univ Pisa, Cardiol, Pisa, Italy
[4] Pisa Univ Hosp, Univ Cardiol Div, Pisa, Italy
[5] Osped Apuane, Cardiol, Massa, Italy
[6] Univ Pisa, New Santa Chiara Hosp, Cardiac & Thorac Dept, Div Cardiovasc Dis 2, Pisa, Italy
[7] Livorno Hosp, Cardiol Div, Livorno, Italy
[8] Azienda Osped Univ Careggi, SODC Geriatria UTIG, Florence, Italy
[9] Villamarina Hosp, Cardiol, Piombino, Italy
[10] Versilia Hosp Azienda Usl Toscana Nord Ovest, Med Oncol, Lido Di Camaiore, Italy
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2024年 / 26卷
关键词：
D O I：
10.1093/eurheartjsupp/suae036.300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
suae036.30
引用
收藏
页码：ii120 / ii120
页数：1
相关论文
共 50 条
  • [21] The Clinical Efficacy and Safety of SGLT2 Inhibitors in Japanese Patients with Type 2 Diabetes
    Tosaki, Takahiro
    Kamiya, Hideki
    Kato, Yoshiro
    Kondo, Masaki
    Nakamura, Jiro
    DIABETES, 2015, 64 : A154 - A155
  • [22] Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
    Patel, Anupa K.
    Fonseca, Vivian
    CURRENT DIABETES REPORTS, 2010, 10 (02) : 101 - 107
  • [23] Fournier gangrene: new safety concern of SGLT2 inhibitors
    Reactions Weekly, 2019, 1753 (1) : 8 - 8
  • [24] Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
    Anupa K. Patel
    Vivian Fonseca
    Current Diabetes Reports, 2010, 10 : 101 - 107
  • [25] Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
    Qiu, Mei
    Ding, Liang-Liang
    Zhang, Miao
    Zhou, Hai-Rong
    DIABETES & VASCULAR DISEASE RESEARCH, 2021, 18 (02):
  • [26] Safety of SGLT2 Inhibitors in CKD Walking the Fine Line
    Dobre, Mirela
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (06): : 774 - 776
  • [27] A Review on the Relationship between SGLT2 Inhibitors and Cancer
    Lin, Hao-Wen
    Tseng, Chin-Hsiao
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2014, 2014
  • [28] Research Progress of SGLT2 Inhibitors in Cancer Treatment
    Miao, Xiaoyong
    Zhang, Jianing
    Huang, Weiyan
    Wang, Yifei
    Jin, Aixia
    Cao, Jianping
    Zhao, Zhenzhen
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 505 - 514
  • [29] Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies
    Ahmed Elkeraie
    Rowan Zyada
    Mahmoud E. Elrggal
    Mohamed Elrggal
    European Journal of Clinical Pharmacology, 2023, 79 : 961 - 966
  • [30] Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies
    Elkeraie, Ahmed
    Zyada, Rowan
    Elrggal, Mahmoud E.
    Elrggal, Mohamed
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (07) : 961 - 966
12345